Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2017

Collaborative Arrangement with Ipsen [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Schedule of Collaborative Revenues Under Collaboration Agreement

During the three and six months ended June 30, 2017 and 2016, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):



	Three Months Ended June 30,					Six Months Ended June 30,
	2017			2016		2017			2016
Amortization of upfront payments and deferred milestone	$	4,741		$	3,592	$	9,046		$	4,790
Royalty revenue	219			—		443			—
Development cost reimbursements	862			—		1,199			—
Product supply agreement revenue	811			—		1,802			—
Cost of supplied product	(811		)	—		(1,802		)	—
Royalty payable to GSK on net sales by Ipsen	(328		)	—		(664		)	—
Collaboration revenues under the Ipsen Collaboration Agreement	$	5,494		$	3,592	$	10,024		$	4,790

Collaborative Arrangement with Genentech [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Schedule of Collaborative Revenues Under Collaboration Agreement

During the three and six months ended June 30, 2017 and 2016, ex-U.S. royalty revenues and U.S. losses under the Genentech Collaboration Agreement were as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues	$	1,367		$	1,042		$	3,665		$	1,172
U.S. losses included in Selling, general and administrative expenses⁽¹⁾	$	(781	)	$	(4,630	)	$	(1,407	)	$	(11,923	)

____________________


(1)	A portion of the accrual for losses for three and six months ended June 30, 2016 were reversed in December 2016 when we were relieved of our obligation to pay certain disputed costs as a result of Genentech’s unilaterally change to its approach to the allocation of promotional expenses arising from commercialization of the COTELLIC plus Zelboraf combination therapy.

Collaborative Arrangement with Takeda [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Schedule of Collaborative Revenues Under Collaboration Agreement

During the three and six months ended June 30, 2017, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):



	Three Months Ended June 30, 2017		Six Months Ended June 30, 2017
Amortization of upfront payment	$	2,830	$	4,717
Development cost reimbursements	1,313		2,108
Collaboration revenues under the Takeda Collaboration Agreement	$	4,143	$	6,825

Collaborative Arrangements with Glaxo Smith Kline [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Schedule of Collaborative Revenues Under Collaboration Agreement

During the three and six months ended June 30, 2017 and 2016, royalties earned by GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Royalties earned by GSK	$	2,962	$	946	$	5,363	$	1,218